Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other financing activities: 2023-2025

Historic Other financing activities for Compass Therapeutics (CMPX) over the last 1 years, with Sep 2025 value amounting to $8.6 million.

  • Compass Therapeutics' Other financing activities rose 431800.00% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 2868.04%. This contributed to the annual value of $543,000 for FY2024, which is 441.51% up from last year.
  • Latest data reveals that Compass Therapeutics reported Other financing activities of $8.6 million as of Q3 2025, which was up 432,000.00% from -$2,000 recorded in Q4 2024.
  • Compass Therapeutics' Other financing activities' 5-year high stood at $8.6 million during Q3 2025, with a 5-year trough of -$254,000 in Q4 2023.
  • Its 3-year average for Other financing activities is $1.5 million, with a median of $500 in 2024.
  • Data for Compass Therapeutics' Other financing activities shows a peak YoY surged of 431,800.00% (in 2025) over the last 5 years.
  • Compass Therapeutics' Other financing activities (Quarterly) stood at -$254,000 in 2023, then spiked by 99.21% to -$2,000 in 2024, then surged by 431,800.00% to $8.6 million in 2025.
  • Its last three reported values are $8.6 million in Q3 2025, -$2,000 for Q4 2024, and $2,000 during Q3 2024.